Research

Publications

Below you can find a list of our published research.

9543 results

Cited 22 times since 2019 (3.7 per year) source: EuropePMC

Infection and immunity, Volume 87, Issue 12, 18 3 2019, Pages e00178-19 Coxiella burnetii Intratracheal Aerosol Infection Model in Mice, Guinea Pigs, and Nonhuman Primates. Gregory AE, van Schaik EJ, Russell-Lodrigue KE, Fratzke AP, Samuel JE

Coxiella burnetii, the etiological agent of Q fever, is a Gram-negative bacterium transmitted to humans by inhalation of contaminated aerosols. Acute Q fever is often self-limiting, presenting as a febrile illness that can result in atypical pneumonia. In some cases, Q fever becomes chronic, leading to endocarditis that can be life threatening. The formalin-inactivated whole-cell vaccine (WCV) confers long-term protection but has significant side effects when administered to presensitized indivi... Abstract

Cited 3 times since 2019 (0.5 per year) source: EuropePMC

International journal of cardiology, Volume 306, 16 3 2019, Pages 152-157 Doppler gradients, valve area and ventricular function in pregnant women with aortic or pulmonary valve disease: Left versus right. Siegmund AS, Pieper PG, Mulder BJM, Sieswerda GT, van Dijk APJ, Roos-Hesselink JW, Jongbloed MRM, Konings TC, Bouma BJ, Groen H, Sollie-Szarynska KM, Kampman MAM, Bilardo CM, van Veldhuisen DJ, Aalberts JJJ

Objective: Little is known about the course of echocardiographic parameters used for the evaluation of valvular heart disease (VHD) during pregnancy, hampering interpretation of possible changes (physiological vs. pathophysiological). Therefore we studied the course of these parameters and ventricular function in pregnant women with aortic and pulmonary VHD. Methods: The cohort comprised 66 pregnant women enrolled in the prospective ZAHARA studies or evaluated by an identical protocol who had pu... Abstract

Cited 1 times since 2019 (0.2 per year) source: EuropePMC

PloS one, Volume 14, Issue 11, 14 2 2019, Pages e0225493 Correction: The modulation of facial mimicry by attachment tendencies and their underlying affiliation motives in 3-year-olds: An EMG study. Vacaru SV, van Schaik JE, Hunnius S

[This corrects the article DOI: 10.1371/journal.pone.0218676.]. Abstract

Cited 15 times since 2019 (2.5 per year) source: EuropePMC

Science advances, Volume 5, Issue 11, 13 2 2019, Pages eaax6656 Role of climate in the rise and fall of the Neo-Assyrian Empire. Sinha A, Kathayat G, Weiss H, Li H, Cheng H, Reuter J, Schneider AW, Berkelhammer M, Adalı SF, Stott LD, Edwards RL

Northern Iraq was the political and economic center of the Neo-Assyrian Empire (c. 912 to 609 BCE)-the largest and most powerful empire of its time. After more than two centuries of regional dominance, the Neo-Assyrian state plummeted from its zenith (c. 670 BCE) to complete political collapse (c. 615 to 609 BCE). Earlier explanations for the Assyrian collapse focused on the roles of internal politico-economic conflicts, territorial overextension, and military defeat. Here, we present a high-res... Abstract

Cited 1 times since 2019 (0.2 per year) source: EuropePMC

JACC. Cardiovascular imaging, Volume 13, Issue 2 Pt 1, 13 2 2019, Pages 526-528 Out of Focus: Increase of the Excess Longitudinal Range in Coronary Computed Tomographic Angiography. Stocker TJ, Heckner M, Leipsic J, Hadamitzky M, Deseive S, Achenbach S, Chen MY, Rubinshtein R, Bax JJ, Bittencourt MS, Jadhav UM, Schlosser T, Ramanathan S, Yu JH, Massberg S, Hausleiter J

Abstract

Cited 58 times since 2019 (9.6 per year) source: EuropePMC

JACC. Cardiovascular imaging, Volume 13, Issue 6, 13 2 2019, Pages 1409-1417 Differences in Progression to Obstructive Lesions per High-Risk Plaque Features and Plaque Volumes With CCTA. Lee SE, Sung JM, Andreini D, Al-Mallah MH, Budoff MJ, Cademartiri F, Chinnaiyan K, Choi JH, Chun EJ, Conte E, Gottlieb I, Hadamitzky M, Kim YJ, Lee BK, Leipsic JA, Maffei E, Marques H, de Araújo Gonçalves P, Pontone G, Raff GL, Shin S, Stone PH, Samady H, Virmani R, Narula J, Berman DS, Shaw LJ, Bax JJ, Lin FY, Min JK, Chang HJ

Objectives: This study explored whether the pattern of nonobstructive lesion progression into obstructive lesions would differ according to the presence of high-risk plaque (HRP). Background: It is still debatable whether HRP simply represents a certain phase during the natural history of coronary atherosclerotic plaques or if disease progression would differ according to the presence of HRP. Methods: Patients with nonobstructive coronary artery disease, defined as percent diameter stenosis (%DS... Abstract

Cited 53 times since 2019 (8.8 per year) source: EuropePMC

European journal of heart failure, Volume 22, Issue 7, 11 2 2019, Pages 1147-1155 Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. Nauta JF, Hummel YM, Tromp J, Ouwerkerk W, van der Meer P, Jin X, Lam CSP, Bax JJ, Metra M, Samani NJ, Ponikowski P, Dickstein K, Anker SD, Lang CC, Ng LL, Zannad F, Filippatos GS, van Veldhuisen DJ, van Melle JP, Voors AA

Aims: Heart failure is traditionally classified by left ventricular ejection fraction (LVEF), rather than by left ventricular (LV) geometry, with guideline-recommended therapies in heart failure with reduced ejection fraction (HFrEF) but not heart failure with preserved ejection fraction (HFpEF). Most patients with HFrEF have eccentric LV hypertrophy, but some have concentric LV hypertrophy. We aimed to compare clinical characteristics, biomarker patterns, and response to treatment of patients w... Abstract

Cited 90 times since 2019 (14.9 per year) source: EuropePMC

Circulation, Volume 140, Issue 25, 11 2 2019, Pages 2054-2062 Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. Jukema JW, Zijlstra LE, Bhatt DL, Bittner VA, Diaz R, Drexel H, Goodman SG, Kim YU, Pordy R, Reiner Ž, Roe MT, Tse HF, Montenegro Valdovinos PC, White HD, Zeiher AM, Szarek M, Schwartz GG, Steg PG, ODYSSEY OUTCOMES Investigators

Background: Lowering of atherogenic lipoproteins, including low-density lipoprotein cholesterol (LDL-C), reduces the risk of ischemic stroke. However, concerns have been raised about very low LDL-C levels and a potential increased risk of hemorrhagic stroke. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome and elevated atherogenic lipoproteins, despite intensive statin therapy, targeting LDL-C levels of 25 to 50 mg/dL an... Abstract

Cited 165 times since 2019 (27.3 per year) source: EuropePMC

Neurology, Volume 93, Issue 24, 11 2 2019, Pages e2257-e2271 Profile of and risk factors for poststroke cognitive impairment in diverse ethnoregional groups. Lo JW, Crawford JD, Desmond DW, Godefroy O, Jokinen H, Mahinrad S, Bae HJ, Lim JS, Köhler S, Douven E, Staals J, Chen C, Xu X, Chong EJ, Akinyemi RO, Kalaria RN, Ogunniyi A, Barbay M, Roussel M, Lee BC, Srikanth VK, Moran C, Kandiah N, Chander RJ, Sabayan B, Jukema JW, Melkas S, Erkinjuntti T, Brodaty H, Bordet R, Bombois S, Hénon H, Lipnicki DM, Kochan NA, Sachdev PS, Stroke and Cognition (STROKOG) Collaboration

Objective: To address the variability in prevalence estimates and inconsistencies in potential risk factors for poststroke cognitive impairment (PSCI) using a standardized approach and individual participant data (IPD) from international cohorts in the Stroke and Cognition Consortium (STROKOG) consortium. Methods: We harmonized data from 13 studies based in 8 countries. Neuropsychological test scores 2 to 6 months after stroke or TIA and appropriate normative data were used to calculate standard... Abstract

Cited 12 times since 2019 (2 per year) source: EuropePMC

Circulation. Cardiovascular quality and outcomes, Volume 12, Issue 11, 11 2 2019, Pages e005858 Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. Szarek M, Steg PG, DiCenso D, Bhatt DL, Bittner VA, Budaj A, Diaz R, Goodman SG, Gotcheva N, Jukema JW, Pordy R, Roe MT, Sourdille T, White HD, Xavier D, Zeiher AM, Schwartz GG

Background: In ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), alirocumab was compared with placebo, added to high-intensity or maximum tolerated statin treatment after acute coronary syndrome in 18 924 patients. Alirocumab reduced first occurrence of the primary composite end point-coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or hospitalization for unstable angina-as w... Abstract

Cited 6 times since 2019 (1 per year) source: EuropePMC

Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, Volume 25, Issue 3, 10 2 2019, Pages e12722 An initial exploration of subtraction electrocardiography to detect myocardial ischemia in the prehospital setting. Ter Haar CC, Peters RJG, Bosch J, Sbrollini A, Gripenstedt S, Adams R, Bleijenberg E, Kirchhof CJHJ, Alizadeh Dehnavi R, Burattini L, de Winter RJ, Macfarlane PW, Postema PG, Man S, Scherptong RWC, Schalij MJ, Maan AC, Swenne CA

Background: In the prehospital triage of patients presenting with symptoms suggestive of acute myocardial ischemia, reliable myocardial ischemia detection in the electrocardiogram (ECG) is pivotal. Due to large interindividual variability and overlap between ischemic and nonischemic ECG-patterns, incorporation of a previous elective (reference) ECG may improve accuracy. The aim of the current study was to explore the potential value of serial ECG analysis using subtraction electrocardiography. M... Abstract

Cited 12 times since 2019 (2 per year) source: EuropePMC

European journal of neurology, Volume 27, Issue 3, 7 1 2019, Pages 506-513 Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study. Adrichem ME, Bus SR, Wieske L, Mohammed H, Verhamme C, Hadden R, van Schaik IN, Eftimov F

Background and purpose: We hypothesized that combining intravenous immunoglobulin (IVIg) and intravenous methylprednisolone (IVMP) leads to more frequent remission compared with IVIg alone while maintaining the fast efficacy of IVIg. In this uncontrolled pilot study, we evaluated remission, rate of improvement and safety in patients with chronic inflammatory demyelinating polyradiculoneuropathy receiving induction treatment with combined IVIg and IVMP. Methods: Consecutive treatment-naive patien... Abstract

Cancer treatment reviews, Volume 81, 6 1 2019, Pages 101913 Corrigendum to "Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors" [Cancer Treatm. Rev. 74 (2019) 21-28]. Fogli S, Del Re M, Curigliano G, van Schaik RH, Lancellotti P, Danesi R

Abstract

Cited 37 times since 2019 (6.1 per year) source: EuropePMC

Clinical pharmacology and therapeutics, Volume 107, Issue 1, 6 1 2019, Pages 57-61 Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities. Chenoweth MJ, Giacomini KM, Pirmohamed M, Hill SL, van Schaik RHN, Schwab M, Shuldiner AR, Relling MV, Tyndale RF

Abstract

Pharmacogenomics, Volume 20, Issue 18, 6 1 2019, Pages 1247-1249 Circulating biomarkers of response to immunotherapy in cancer treatment. Del Re M, Gianfilippo G, Crucitta S, Addeo A, van Schaik RH, Danesi R

Abstract

Frontiers in veterinary science, Volume 6, 6 1 2019, Pages 375 Assessing the Adoption of Recommended Standards, Novel Approaches, and Best Practices for Animal Health Surveillance by Decision Makers in Europe. Häsler B, Garza M, Bisdorff B, Léger A, Tavornpanich S, Peyre M, Lindberg A, van Schaik G, Alban L, Stärk KDC

Animal health surveillance is an important tool for disease mitigation and helps to promote animal health and welfare, protect human health, support efficient animal production, and enable trade. This study aimed to assess adoption of recommended standards and best practice for surveillance (including risk-based approaches) in Europe. It included scoping interviews with surveillance experts in Denmark, the Netherlands, Norway, and Switzerland to gather information on knowledge acquisition, decis... Abstract

Cited 23 times since 2019 (3.8 per year) source: EuropePMC

Urologic oncology, Volume 38, Issue 5, 5 1 2019, Pages 440-448 Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019? Hentschel AE, van Rhijn BWG, Bründl J, Compérat EM, Plass K, Rodríguez O, Henríquez JDS, Hernández V, de la Peña E, Alemany I, Turturica D, Pisano F, Soria F, Čapoun O, Bauerová L, Pešl M, Bruins HM, Runneboom W, Herdegen S, Breyer J, Brisuda A, Scavarda-Lamberti A, Calatrava A, Rubio-Briones J, Seles M, Mannweiler S, Bosschieter J, Kusuma VRM, Ashabere D, Huebner N, Cotte J, Mertens LS, Cohen D, Lunelli L, Cussenot O, Sheikh SE, Volanis D, Coté JF, Rouprêt M, Haitel A, Shariat SF, Mostafid AH, Nieuwenhuijzen JA, Zigeuner R, Dominguez-Escrig JL, Hacek J, Zlotta AR, Burger M, Evert M, Hulsbergen-van de Kaa CA, van der Heijden AG, Kiemeney LALM, Soukup V, Molinaro L, Gontero P, Llorente C, Algaba F, Palou J, N'Dow J, Babjuk M, van der Kwast TH, Sylvester RJ

Background: Papillary urothelial neoplasm of low malignant potential (PUN-LMP) was introduced as a noninvasive, noncancerous lesion and a separate grade category in 1998. Subsequently, PUN-LMP was reconfirmed by World Health Organization (WHO) 2004 and WHO 2016 classifications for urothelial bladder tumors. Objectives: To analyze the proportion of PUN-LMP diagnosis over time and to determine its prognostic value compared to Ta-LG (low-grade) and Ta-HG (high-grade) carcinomas. To assess the intra... Abstract

Cited 16 times since 2019 (2.6 per year) source: EuropePMC

BMC neurology, Volume 19, Issue 1, 4 1 2019, Pages 265 Determinants of extended door-to-needle time in acute ischemic stroke and its influence on in-hospital mortality: results of a nationwide Dutch clinical audit. Kuhrij LS, Marang-van de Mheen PJ, van den Berg-Vos RM, de Leeuw FE, Nederkoorn PJ, Dutch Acute Stroke Audit consortium

Background: Intravenous thrombolysis (IVT) plays a prominent role in the treatment of acute ischemic stroke (AIS). The sooner IVT is administered, the higher the odds of a good outcome. Therefore, registering the in-hospital time to treatment with IVT, i.e. the door-to-needle time (DNT), is a powerful way to measure quality improvement. The aim of this study was to identify determinants that are associated with extended DNT. Methods: Patients receiving IVT in 2015 and 2016 registered in the Dutc... Abstract

Cited 4 times since 2019 (0.7 per year) source: EuropePMC

The Journal of thoracic and cardiovascular surgery, Volume 161, Issue 1, 2 1 2019, Pages 66-75.e4 Antithrombotic therapy and bleeding events after aortic valve replacement with a novel bioprosthesis. Klautz RJM, Vriesendorp MD, Dagenais F, Labrousse L, Bapat V, Moront MG, Misfeld M, Gearhart E, Kappetein AP, Sabik JF

Objective: Several recent-generation surgical tissue valves have been found to have bleeding rates exceeding rates recommended by regulatory bodies. We explored bleeding events using data from the Pericardial Surgical Aortic Valve Replacement (PERIGON) Pivotal Trial for the Avalus valve (Medtronic, Minneapolis, Minn) to examine whether this end point remains relevant for the evaluation of bioprostheses. Methods: Patients (n = 1115) underwent aortic valve replacement. Bleeding and thromboembolic... Abstract

Cited 17 times since 2019 (2.8 per year) source: EuropePMC

American journal of hypertension, Volume 32, Issue 12, 1 1 2019, Pages 1146-1153 Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group. Irvin MR, Sitlani CM, Floyd JS, Psaty BM, Bis JC, Wiggins KL, Whitsel EA, Sturmer T, Stewart J, Raffield L, Sun F, Liu CT, Xu H, Cupples AL, Tanner RM, Rossing P, Smith A, Zilhão NR, Launer LJ, Noordam R, Rotter JI, Yao J, Li X, Guo X, Limdi N, Sundaresan A, Lange L, Correa A, Stott DJ, Ford I, Jukema JW, Gudnason V, Mook-Kanamori DO, Trompet S, Palmas W, Warren HR, Hellwege JN, Giri A, O'donnell C, Hung AM, Edwards TL, Ahluwalia TS, Arnett DK, Avery CL

Background: Only a handful of genetic discovery efforts in apparent treatment-resistant hypertension (aTRH) have been described. Methods: We conducted a case-control genome-wide association study of aTRH among persons treated for hypertension, using data from 10 cohorts of European ancestry (EA) and 5 cohorts of African ancestry (AA). Cases were treated with 3 different antihypertensive medication classes and had blood pressure (BP) above goal (systolic BP ≥ 140 mm Hg and/or diastolic BP ≥ 90 mm... Abstract